Want to see AVNS full AI Analyst Report?
AVNS Stock Chart & Stats
$11.84
-$0.16(-1.03%)
At close: 4:00 PM EST
$11.84
-$0.16(-1.03%)
Day’s Range― - ―
52-Week Range$9.30 - $25.49
Previous CloseN/A
Volume92.13K
Average Volume (3M)533.25K
Market Cap
$1.17B
Enterprise Value$1.24B
Total Cash (Recent Filing)$65.60M
Total Debt (Recent Filing)$138.40M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 11, 2026EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding46,847,816
10 Day Avg. Volume604,609
30 Day Avg. Volume533,252
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.67
Price to Sales (P/S)0.74
P/FCF Ratio12.09
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue1.73
Enterprise Value/Gross Profit3.56
Enterprise Value/Ebitda-57.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1
Revenue Forecast (FY)$710.00M
Bulls Say, Bears Say
Bulls Say
Business DevelopmentsAVNS recorded some positive developments during the quarter, which include completing the divestiture of its respiratory health business, exceeding internal expectations on its Trident U.S. market launch, as well as improving its capital position.
Financial PerformanceAvanos Medical posted a moderate quarterly beat on both the top and bottom lines, with a strong quarter from its Digestive Health business.
Bears Say
Guidance And Market ConditionsManagement's initial full-year 2025 guidance was light of Street expectations, calling for flat to slight declines in both revenue and earnings, reflecting a challenging market environment for some of its product categories, currency headwinds, and other macro factors.
Pricing PressuresThe hyaluronic acid injection business continues to be a sore spot with ongoing pricing pressures highlighted as a key factor underpinning the company’s below-Consensus initial 2025 guidance.
Avanos Medical News
AVNS FAQ
What was Avanos Medical’s price range in the past 12 months?
Avanos Medical lowest stock price was $9.30 and its highest was $25.49 in the past 12 months.
What is Avanos Medical’s market cap?
Avanos Medical’s market cap is $1.17B.
When is Avanos Medical’s upcoming earnings report date?
Avanos Medical’s upcoming earnings report date is Aug 11, 2026 which is in 31 days.
How were Avanos Medical’s earnings last quarter?
Avanos Medical released its earnings results on May 05, 2026. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.08.
Is Avanos Medical overvalued?
According to Wall Street analysts Avanos Medical’s price is currently Overvalued.
Does Avanos Medical pay dividends?
Avanos Medical does not currently pay dividends.
What is Avanos Medical’s EPS estimate?
Avanos Medical’s EPS estimate is 0.16.
How many shares outstanding does Avanos Medical have?
Avanos Medical has 46,847,816 shares outstanding.
What happened to Avanos Medical’s price movement after its last earnings report?
Avanos Medical reported an EPS of $0.22 in its last earnings report, beating expectations of $0.14. Following the earnings report the stock price went up 0.162%.
Which hedge fund is a major shareholder of Avanos Medical?
Currently, no hedge funds are holding shares in AVNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avanos Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AVNS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 346.3K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.00%
12-Months-Change
Fundamentals
Return on Equity
-8.91%
Trailing 12-Months
Asset Growth
-5.21%
Trailing 12-Months
Company Description
Avanos Medical
Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.
AVNS Company Deck
AVNS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid operational execution and portfolio reshaping that produced revenue outperformance, margin expansion in key segments, strong cash generation, and successful M&A integration (Nexus). However, a material near-term headwind from tariffs (approximately $30M expected in 2026) and lingering softness in certain product lines (surgical pain, GAME READY, HA/IV exits) will weigh on margins in the near term. Management presented a credible mitigation path (China exit, production shift to Mexico/SE Asia, cost containment, pricing) and provided constructive 2026 guidance, indicating confidence in returning to margin improvement in H2 2026 and beyond.View all AVNS earnings summariesTechnical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
1.95% Insiders
26.40% Mutual Funds
1.55% Other Institutional Investors
47.83% Public Companies and
Individual Investors











